A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Johnson & Johnson Private Limited to Johnson & Johnson Private Limited
    • Eligibility criteria expanded, about 10 words
    • Site details revised at 2 of 12 sites
  2. Study completion moved earlier from Jun 20, 2027 to Feb 14, 2027v15
  3. Enrollment closed, study ongoing
    • Site details revised at 12 of 12 sites
    v14
  4. 5 versions Re-verified since Mar 12, 2026, no change to tracked fieldsv9-v13
  5. Study sites: 11 to 12v8
Show 6 earlier versionsHide 6 earlier versions
  1. Eligibility criteria expanded, about 73 words
    • Secondary endpoints: details revised at 2 of 2 entries
    v7
  2. Study sites: 8 to 11v6
  3. Study sites: 7 to 8v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study sites: 4 to 7v3
  6. Study sites: 3 to 4v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.
Trial Details
NCT Number NCT07030517
Lead Sponsor Johnson & Johnson Private Limited
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov